Vascular endothelial growth factor

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)

Retrieved on: 
Monday, January 13, 2020

Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientiststo develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.

Key Points: 
  • Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientiststo develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.
  • Exonate has developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing.
  • Commenting on the announcement, Dr. Catherine Beech CEO of Exonate, said: "I am absolutely delighted to enter this strategic collaboration with Janssen, we are looking forward to successfully developing a novel treatment for retinal neovascular diseases."
  • Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months.

Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseases Including Wet Age-related Macular degeneration (AMD) and Diabetic Macular Oedema (DMO)

Retrieved on: 
Monday, January 13, 2020

Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientiststo develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.

Key Points: 
  • Through the collaboration, Exonate will work with Janssen Research & Development, LLC scientiststo develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.
  • Exonate has developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing.
  • Commenting on the announcement, Dr. Catherine Beech CEO of Exonate, said: "I am absolutely delighted to enter this strategic collaboration with Janssen, we are looking forward to successfully developing a novel treatment for retinal neovascular diseases."
  • Unlike small molecule drugs or eye drops these treatments must be injected into the eye once every 1 or 2 months.

Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

Retrieved on: 
Tuesday, January 7, 2020

Patients recruited into the study had a history of response to prior anti-VEGF and/or corticosteroid treatment.

Key Points: 
  • Patients recruited into the study had a history of response to prior anti-VEGF and/or corticosteroid treatment.
  • At baseline, the study patient population had a mean BCVA of 56 letters, and a mean Central Subfield Thickness (CST) of 542m.
  • Topline data from the trial show that THR-687 is well-tolerated and safe with no dose-limiting toxicities.
  • THR-149, the Companys other and most advanced VEGF-independent treatment also delivered positive Phase 1 results in July 2019.

Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME

Retrieved on: 
Thursday, December 19, 2019

Oxurions clinical pipeline now comprises:

Key Points: 
  • Oxurions clinical pipeline now comprises:
    THR-149, which has shown positive topline Phase 1 results for the treatment of DME.
  • THR-687, which is in a Phase 1 clinical study assessing it as a treatment for DME.
  • There is clear need for novel medicines that act via VEGF independent pathways, to address many of the limitations of the VEGF inhibitors, the current standard of care for DME.
  • It is estimated that 40% of DME patients treated with anti-VEGF do not, or sub optimally respond to anti-VEGF treatment.

Chi-Med Highlights Oral Presentations at 2019 ESMO Asia Annual Meeting

Retrieved on: 
Saturday, November 23, 2019

Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3.

Key Points: 
  • Fruquintinib is a highly selective and potent oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3.
  • Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage.
  • Chi-Med retains all rights to fruquintinib outside of China and is partnered with Eli Lilly and Company in China.
  • Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products.

Ascendis Pharma A/S Announces First Presentation of Preclinical Data Utilizing TransCon™ Technology in Oncology at SITC 2019

Retrieved on: 
Wednesday, November 6, 2019

TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod that is transiently conjugated to a hydrogel carrier via a TransCon linker.

Key Points: 
  • TransCon TLR7/8 Agonist is a long-acting prodrug of resiquimod that is transiently conjugated to a hydrogel carrier via a TransCon linker.
  • Administered as an intratumoral injection, TransCon TLR7/8 Agonist is designed to provide sustained release of unmodified resiquimod directly to the tumor.
  • Three oncology programs are currently in preclinical studies: TransCon TLR7/8 Agonist, TransCon IL-2 b/g and TransCon Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor (VEGF-TKI).
  • Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group.

Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels

Retrieved on: 
Friday, November 1, 2019

Regen BioPharma, Inc. has been utilizing NR2F6 as a target for immune modulation and cancer stem cells.To the Company's knowledge, this is the first indication to date that NR2F6 is involved in the formation of new blood vessels.

Key Points: 
  • Regen BioPharma, Inc. has been utilizing NR2F6 as a target for immune modulation and cancer stem cells.To the Company's knowledge, this is the first indication to date that NR2F6 is involved in the formation of new blood vessels.
  • "In our experiments, we observed that inhibition of NR2F6 selectively blocked multiplication of blood vessel cells that were stimulated withVascular Endothelial Growth Factor (VEGF).
  • Since VEGF is associated with disease conditions, it is possible that our approach possesses some degree of specificity in blocking pathological but not healthy formation of new blood vessels.
  • New blood vessels suggests that this approach may not suppress healthy blood vessels which are primarily formed independently of VEGF."

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Retrieved on: 
Saturday, October 12, 2019

In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.

Key Points: 
  • In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.
  • Through week 104, patients received Abicipar 2 mg every 8-weeks or every 12-weeks or ranibizumab 0.5 mg every 4 weeks.
  • At week 104 in the pooled Phase 3 data, the proportion of patients with stable vision was 93%, 90% and 94% in 8-week Abicipar; 12-week Abicipar and 4-week ranibizumab treatment regimens, respectively.
  • "Current anti-VEGF treatments for neovascular age-related macular degeneration require frequent intravitreal injections," said Rahul N. Khurana, M.D., Northern California Retina Vitreous Associates Medical Group.

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

Retrieved on: 
Thursday, October 10, 2019

The expansion builds on the existing global collaboration agreement between the two companies on sintilimab in combination with Chi-Meds highly selective VEGFR inhibitor, fruquintinib.

Key Points: 
  • The expansion builds on the existing global collaboration agreement between the two companies on sintilimab in combination with Chi-Meds highly selective VEGFR inhibitor, fruquintinib.
  • The expansion of the global collaboration will allow Innovent and Chi-Med to jointly explore the potential application of Tyvyt and surufatinib combination therapy in solid tumors with global unmet medical needs.
  • Sintilimab, co-developed by Innovent and Eli Lilly and Company, has gained broad recognition by the market, due to its profiles in safety and efficacy.
  • We are excited to further collaborate with Chi-Med to develop the combination therapy of sintilimab and surufatinib, hoping more patients will benefit from this potential therapy globally.

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

Retrieved on: 
Thursday, October 10, 2019

The expansion builds on the existing global collaboration agreement between the two companies on sintilimab in combination with Chi-Med's highly selective VEGFR inhibitor, fruquintinib.

Key Points: 
  • The expansion builds on the existing global collaboration agreement between the two companies on sintilimab in combination with Chi-Med's highly selective VEGFR inhibitor, fruquintinib.
  • The expansion of the global collaboration will allow Innovent and Chi-Med to jointly explore the potential application of Tyvyt and surufatinib combination therapy in solid tumors with global unmet medical needs.
  • "Sintilimab, co-developed by Innovent and Eli Lilly and Company, has gained broad recognition by the market, due to its profiles in safety and efficacy.
  • "We are excited to further collaborate with Chi-Med to develop the combination therapy of sintilimab and surufatinib, hoping more patients will benefit from this potential therapy globally."